Hennion & Walsh Asset Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 168,324 shares of VRDN stock, worth $2.83 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
168,324
Previous 199,193
15.5%
Holding current value
$2.83 Million
Previous $2.88 Million
18.18%
% of portfolio
0.1%
Previous 0.13%
Shares
9 transactions
Others Institutions Holding VRDN
# of Institutions
187Shares Held
79.8MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$90.5 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$80.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$79.1 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$76.8 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$65.3 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $671M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...